课题基金 / 基金详情

项目摘要

项目成果

HENRY Isaac MOSBERG的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):阿片类药物的合理设计需要详细了解阿片配体和阿片受体之间的精确相互作用,这些相互作用是特定阿片受体的配体选择性的基础,并区分激动剂和拮抗剂功能。在当前的资助期内,我们为获得这种理解所做的努力集中在μ和δ阿片受体(莫尔和DOR)的配体/受体复合物模型的完善和验证,以及阐明区分与莫尔和DOR结合的配体-受体相互作用的精确特征。在下一个资助期内,我们建议通过应用从初始环状KOR(κ阿片受体)肽配体获得的见解来扩展这些研究,这些肽配体显示出高亲和力但是非选择性的,并且从我们的莫尔,DOR和KOR的配体-受体相互作用模型来设计相同系列中的新KOR配体,通过KOR特异性受体相互作用实现KOR选择性。我们也将开始一个类似的过程,孤儿受体,ORL 1的结构为基础的配体设计,使用环状五肽支架。如果成功,这些研究将代表所有4类阿片受体的结构相关选择性配体的基于结构的设计的相当大的成就,其中两种(KOR和ORL 1)通常仅结合较大的肽配体。此外,我们还将跟进令人兴奋的初步结果,这些结果指向决定疗效的特征。这些研究的成功将是配体/受体相互作用模型的准确性和我们的方法对广泛的GPCR的适用性的明确指标。最后,我们将继续我们的努力,旨在转移肽衍生的药效团信息的肽模拟物支架,持有更大的潜力,作为可能的中枢神经系统活性的临床药物。公共卫生相关性:阿片类药物与其蛋白质靶点的相互作用引发了这些药物的理想和不良作用。准确了解这些相互作用是设计和开发具有更有针对性的作用的阿片类药物的第一步,特别是耐受性、依赖性和滥用潜力降低的阿片类药物。
英文摘要
DESCRIPTION (provided by applicant): The rational design of opioid drugs requires a detailed understanding of the precise interactions between opioid ligand and opioid receptor that underlie ligand selectivity for a particular opioid receptor and that distinguish agonist from antagonist function. During the current grant period our efforts to gain that understanding have focused on the refinement and validation of models of ligand/receptor complexes for the mu and delta opioid receptors (MOR and DOR) and elucidation of the precise features of ligand-receptor interaction that differentiate binding to MOR and DOR. In the next grant period, we propose to extend these studies by applying the insights gained from initial cyclic KOR (kappa opioid receptor) peptide ligands that display high affinity but are nonselective, and from our ligand-receptor interaction models for MOR, DOR, and KOR to design new KOR ligands within the same series that achieve KOR selectivity through KOR-specific receptor interactions. We will also begin a similar process of structure based ligand design for the orphan receptor, ORL1, using a cyclic pentapeptide scaffold. If successful, these studies would represent the considerable achievement of structure-based design of structurally related selective ligands for all 4 classes of opioid receptors, two of which (KOR and ORL1) typically bind only larger peptide ligands. Further, we will follow-up exciting initial results that point to features that determine efficacy. Success in these studies would be a clear indicator of the accuracy of the ligand/receptor interaction models and the applicability of our approaches to a wide array of GPCRs. Finally, we will continue our efforts aimed at transferring peptide-derived pharmacophore information to peptidomimetic scaffolds that hold much greater potential as possible CNS active clinical agents. PUBLIC HEALTH RELEVANCE: The interaction of opioid drugs with their protein targets initiates the desirable and undesirable effects of these drugs. Gaining a precise understanding of these interactions is the first step toward the design and development of opioid drugs with more tailored actions, especially opioids with reduced tolerance, dependence liability, and abuse potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RESEARCH FACILITIES CONSTRUCTION
CORE--CHEMICAL SYNTHESIS
CORE--CHEMICAL SYNTHESIS
CORE--CHEMICAL SYNTHESIS
海外基金